Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Mann, der ein Lithium-Unternehmen im Wert von 1,2 Milliarden Dollar aufgebaut hat, ist zurück...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ANGZ | ISIN: FR0013183985 | Ticker-Symbol: G49N
Stuttgart
13.10.25 | 11:17
0,136 Euro
-1,30 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENSIGHT BIOLOGICS SA Chart 1 Jahr
5-Tage-Chart
GENSIGHT BIOLOGICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1400,14112:56

Aktuelle News zur GENSIGHT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiGenSight Biologics Reports Cash Position as of September 30, 2025234Cash position amounted to €0.6 million as of September 30, 2025 Successful closing of fundraising worth nearly EUR3.7 million on October 1, 2025 Cash position amounted to €3.6 million...
► Artikel lesen
01.10.GenSight Biologics S.A.: GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million326Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
GENSIGHT BIOLOGICS Aktie jetzt für 0€ handeln
29.09.GenSight Biologics Reports Interim Financial Results for the First Half of 2025356Optimized cash management results in 8.3% reduction in operating cash outflow compared to the same period in 2024 Cash runway extended to late Q4 2025 following post-closing financing ...
► Artikel lesen
26.09.GenSight Biologics S.A.: GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million201Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
28.08.GenSight Biologics S.A.: GenSight Biologics Postpones Release of 2025 Half-Year Financial Results358Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
► Artikel lesen
22.07.GenSight Biologics Announces the Closing of Approximately €500,000 of Additional Financing374Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
17.07.GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ Gene Therapy302Better baseline visual acuity and thicker baseline optical coherence tomography (OCT) parameters predict better final visual outcome Patients treated during dynamic phase achieve better...
► Artikel lesen
17.07.GenSight Biologics Raises Approx. EUR 500K2
17.07.GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder414Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
08.07.GenSight Biologics Reports Cash Position as of June 30, 2025384Operations funded until early October 2025 as a result of disciplined spending controls Agreement with the ANSM to consider opening the Named Early Access Program (AAC) for LUMEVOQ in France...
► Artikel lesen
03.07.GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement442Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
01.07.GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million431Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
26.06.GenSight Transfers Upstream Phase of LUMEVOQ Manufacturing Process to Catalent3
26.06.GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent341Upstream phase of LUMEVOQ manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and...
► Artikel lesen
12.06.GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ Named Early Access Program (AAC) in France509Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application...
► Artikel lesen
13.05.GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025402Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
► Artikel lesen
23.04.GenSight Biologics Annual General Meeting on May 13, 2025543Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused...
► Artikel lesen
08.04.GenSight Biologics S.A.: GenSight Biologics Announces the Filing of its 2024 Universal Registration Document468Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
07.04.GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update436Operations funded until early June 2025 as a result of disciplined spending controls Discussions with French agency ANSM regarding the early access program (AAC) for LUMEVOQ progressing ...
► Artikel lesen
19.03.GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates489Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1